“A favorable effect of HCQ on glucose and lipid metabolism beyond its anti-inflammatory role”
“We describe a case of a young woman with type 1 diabetes whose glycemic control was optimized with the introduction of HCQ as a treatment for her Sjogren syndrome in addition to a subtle yet measurable improvement in her lipid profile.”
“An increasing body of evidence supports the beneficial impacts of HCQ in various ancillary conditions, including diabetes mellitus and dyslipidemia.”
“A 24-year-old woman diagnosed at the age of 11 years with type 1 diabetes mellitus presented at the age of 15 years in 2003 to our institution for continuity of her diabetes care.”
“In September 2011, she was diagnosed with Sjogren syndrome and was started on HCQ 200 mg once daily. An improvement in her glycemic control as evidenced by self glucose monitoring was noted within 1 month of HCQ therapy, with no remarkable hypoglycemic episodes.”
“After reviewing the literature, our case seems to be the first case report of a patient with type 1 diabetes who had improvement in her glycemic control while on HCQ therapy.”
This is a lie by omission. The report below showing the benefits of Chloroquine for Type 1 is from 1984. CHQ works the same way as HCQ and again they are trying their hardest to hide the truth.
“The mechanism by which HCQ works to improve glycemic control in patients with type 1 diabetes is not known and our case seems to be the first case report in the literature.”
“Another report emphasizing the glucose-lowering effect of HCQ is that describing a case of hypoglycemia in a patient with SLE and T2DM after initiation of HCQ at a dose of 200 mg twice daily with eventual discontinuation of her subcutaneous insulin.”
“In conclusion, HCQ is a relatively safe and inexpensive medication and has a favorable glucose and lipid lowering effect that provides a rationale for its use in addition to its known benefits in rheumatic diseases.”
“In vivo chloroquine-induced inhibition of insulin degradation in a diabetic patient with severe insulin resistance”
“We report on a 26-yr-old patient with an 11-yr history of insulin-dependent diabetes mellitus who exhibited insulin resistance with a requirement of up to 15,000 U of intravenous (i.v.) insulin/day.”
“Attempts to diminish her insulin requirement by administration of sulfated insulin or Trasylol were unsuccessful, with the patient remaining resistant to subcutaneous (s.c.) and i.v. administration of pure pork insulin.”
“Chloroquine phosphate therapy (500 mg twice a day) resulted in a decreased requirement for i.v. insulin (700 U/day as compared with the pretreatment requirement of 8400 U/ day).
“This study constitutes the first reported use of chloroquine for treatment of insulin resistance as a result of accelerated insulin degradation, and it provides evidence of the effectiveness of this agent in this rare condition.”
All of my research is free to view, but donations and sponsors are greatly appreciated. I am trying to do this full time now and will need your help to make that happen.
Sponsor on Patreon: https://www.patreon.com/paulmuaddib61